{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T06:27:17Z","timestamp":1697610437384},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,12,8]],"date-time":"2008-12-08T00:00:00Z","timestamp":1228694400000},"content-version":"vor","delay-in-days":2655,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Peptide Research"],"published-print":{"date-parts":[[2001,9]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> Six [Pen<jats:sup>6<\/jats:sup>]oxytocin analogs were synthesized by substituting penicillamine for cysteine in oxytocin, [Mpa<jats:sup>1<\/jats:sup>]oxytocin, [dPen<jats:sup>1<\/jats:sup>]oxytocin, [5\u2010<jats:italic>t<\/jats:italic>\u2010BuPro<jats:sup>7<\/jats:sup>]oxytocin, [Mpa<jats:sup>1<\/jats:sup>, 5\u2010<jats:italic>t<\/jats:italic>\u2010BuPro<jats:sup>7<\/jats:sup>]oxytocin and [dPen<jats:sup>1<\/jats:sup>, 5\u2010<jats:italic>t<\/jats:italic>\u2010BuPro<jats:sup>7<\/jats:sup>]oxytocin. When tested in the uterotonic test <jats:italic>in vitro<\/jats:italic>[Pen<jats:sup>6<\/jats:sup>]oxytocin, [Pen<jats:sup>6<\/jats:sup>, 5\u2010<jats:italic>t<\/jats:italic>\u2010BuPro<jats:sup>7<\/jats:sup>]oxytocin, [Mpa<jats:sup>1<\/jats:sup>, Pen<jats:sup>6<\/jats:sup>]oxytocin and [Mpa<jats:sup>1<\/jats:sup>, Pen<jats:sup>6<\/jats:sup>, 5\u2010<jats:italic>t<\/jats:italic>\u2010BuPro<jats:sup>7<\/jats:sup>]oxytocin, all were found to possess both agonistic and antagonistic properties. Their agonistic potency ranged from negligible (0.08\u2003IU\/mg) to low (5.85\u2003IU\/mg) and their antagonistic potency (pA2) was estimated to range from 6.6 to 7.9. [dPen<jats:sup>1<\/jats:sup>, Pen<jats:sup>6<\/jats:sup>]Oxytocin and [dPen<jats:sup>1<\/jats:sup>, Pen<jats:sup>6<\/jats:sup>, 5\u2010<jats:italic>t<\/jats:italic>\u2010BuPro<jats:sup>7<\/jats:sup>]oxytocin were found to be pure antagonists with similarly high pA2 values of \u2248\u200a8.2. Replacement of proline by 5\u2010<jats:italic>tert<\/jats:italic>\u2010butylproline increased binding affinity by a factor of two in [Pen<jats:sup>6<\/jats:sup>]oxytocin and had no influence on the binding affinity of [Mpa<jats:sup>1<\/jats:sup>, Pen<jats:sup>6<\/jats:sup>]oxytocin and [dPen<jats:sup>1<\/jats:sup>, Pen<jats:sup>6<\/jats:sup>]oxytocin. Assignment of the proton signals for prolyl amide <jats:italic>cis<\/jats:italic>\u2010 and <jats:italic>trans<\/jats:italic>\u2010isomers by NMR experiments in water indicated that the Pen<jats:sup>6<\/jats:sup>\u22125\u2010<jats:italic>tert<\/jats:italic>\u2010BuPro<jats:sup>7<\/jats:sup> peptide bond <jats:italic>cis<\/jats:italic>\u2010isomer population was augmented relative to the prolyl peptides and measured, respectively, at 20, 35 and 35% in the 5\u2010<jats:italic>tert<\/jats:italic>\u2010butylproline<jats:sup>7<\/jats:sup> analogs of [Pen<jats:sup>6<\/jats:sup>]oxytocin, [Mpa<jats:sup>1<\/jats:sup>, Pen<jats:sup>6<\/jats:sup>]oxytocin and [dPen<jats:sup>1<\/jats:sup>, Pen<jats:sup>6<\/jats:sup>]oxytocin. This augmentation in <jats:italic>cis<\/jats:italic>\u2010isomer population was correlated with a 21\u2010fold reduction in the agonistic potency and 2\u2010fold augmentation in antagonistic potency for [Pen<jats:sup>6<\/jats:sup>, 5\u2010<jats:italic>t<\/jats:italic>\u2010BuPro<jats:sup>7<\/jats:sup>]oxytocin relative to [Pen<jats:sup>6<\/jats:sup>]oxytocin. Augmentation of <jats:italic>cis<\/jats:italic>\u2010isomer population was also correlated to reduced agonist potency without effect on antagonism on conversion of [Mpa<jats:sup>1<\/jats:sup>, Pen<jats:sup>6<\/jats:sup>]oxytocin to [Mpa<jats:sup>1<\/jats:sup>, Pen<jats:sup>6<\/jats:sup>, 5\u2010<jats:italic>t<\/jats:italic>\u2010BuPro<jats:sup>7<\/jats:sup>]oxytocin. In the potent oxytocin antagonist, [dPen<jats:sup>1<\/jats:sup>, Pen<jats:sup>6<\/jats:sup>]oxytocin, substitution of 5\u2010<jats:italic>tert<\/jats:italic>\u2010butylproline for proline augmented the <jats:italic>cis<\/jats:italic>\u2010isomer population without affecting antagonistic potency. The synthesis and evaluation of [Pen<jats:sup>6<\/jats:sup>]oxytocin and [Pen<jats:sup>6<\/jats:sup>, 5\u2010<jats:italic>t<\/jats:italic>\u2010BuPro<jats:sup>7<\/jats:sup>]oxytocin analogs 1\u20136 indicated that steric interactions influenced agonist and antagonist activity by modifying peptide conformation. Augmentations in the prolyl <jats:italic>cis<\/jats:italic>\u2010isomer population caused by 5\u2010<jats:italic>tert<\/jats:italic>\u2010butylproline occurred concurrently with enhanced or maintained antagonistic potency and binding affinity and reduced agonistic potency.<\/jats:p>","DOI":"10.1034\/j.1399-3011.2001.00932.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T08:41:05Z","timestamp":1047458465000},"page":"263-273","source":"Crossref","is-referenced-by-count":10,"title":["The influence of steric interactions on the conformation and biology of oxytocin. Synthesis and analysis of penicillamine<sup>6<\/sup>\u2010oxytocin and penicillamine<sup>6<\/sup>\u20105\u2010<i>tert<\/i>\u2010butylproline<sup>7<\/sup>\u2010oxytocin analogs"],"prefix":"10.1111","volume":"58","author":[{"given":"L.","family":"B\u00e9lec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.D.","family":"Lubell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Maletinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Slaninov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,12,8]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00071a019"},{"key":"e_1_2_7_3_2","first-page":"217","article-title":"Analogues of angiotensin II with restricted conformational freedom, including a new antagonist","volume":"12","author":"Turk J.","year":"1976","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00110a010"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00388a027"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00127a004"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja962013b"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-3773(20000317)39:6<1111::AID-ANIE1111>3.0.CO;2-D"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm990090m"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/10799899509045250"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00318a010"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00323a001"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3011.1980.tb02961.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00513a018"},{"key":"e_1_2_7_15_2","first-page":"803","volume-title":"Peptides: Chemistry Structure and Biology","author":"Meraldi J.\u2010P.","year":"1975"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.4.1373"},{"key":"e_1_2_7_17_2","first-page":"375","volume-title":"Peptides: Synthesis Structure Function","author":"Hruby V.J.","year":"1981"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00010a020"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00031a004"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00315a069"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/jo990294a"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(81)90704-1"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4039(01)80764-4"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00017a044"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(00)97936-6"},{"key":"e_1_2_7_26_2","unstructured":"L'Archev\u00eaque B.&Lubell W.D.(1996) Modification de l'\u00c9quilibre des Rotam\u00e8res Cys6\u2010Pro7de l'Oxytocine avec la 5\u2010tert\u2010Butylproline. M\u00e9moire de ma\u00eetrise Universit\u00e9 de Montr\u00e9al."},{"key":"e_1_2_7_27_2","unstructured":"B\u00e9lec L. Slaninov\u00e1 J. Lubell W.D.(2001)Steric interactions of penicillamine6\u20105\u2010tert\u2010butylproline7\u2010oxytocin analogues and their influence on conformation and biological activity. InPeptides 2000: Proceedings of the 26th European Peptide Symposium(Martinez J. &Fehrentz J.\u2010A. eds). EDK Paris France pp.\u2003587\u2013588."},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/10799899909036675"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1021\/jo01015a567"},{"key":"e_1_2_7_30_2","first-page":"55\u201357","volume-title":"Peptides for the New Millennium","author":"Falb E.","year":"2000"}],"container-title":["The Journal of Peptide Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3011.2001.00932.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3011.2001.00932.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1399-3011.2001.00932.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:38:48Z","timestamp":1697524728000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1399-3011.2001.00932.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["10.1034\/j.1399-3011.2001.00932.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1399-3011.2001.00932.x","archive":["Portico"],"relation":{},"ISSN":["1397-002X"],"issn-type":[{"value":"1397-002X","type":"print"}],"subject":[],"published":{"date-parts":[[2001,9]]}}}